Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03438396 · ClinicalTrials.gov registry record · Phase 2
A Trial of Tisotumab Vedotin in Cervical Cancer
A Phase 2 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT03438396 is a Phase 2 study that has completed, run by Seagen. The registered enrollment target is 102 participants.
The verdict
NCT03438396, a Phase 2 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.
Interventions
- DRUG tisotumab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2018-06-12 |
| Est. Completion | 2022-08-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03438396
The ClinicalTrials.gov registry entry for NCT03438396 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tisotumab vedotin is the first listed.
NCT03438396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03438396 about?
NCT03438396 is a clinical study titled "A Trial of Tisotumab Vedotin in Cervical Cancer". A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.
What is the current status of trial NCT03438396?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2018-06-12. Estimated completion is 2022-08-02.
What interventions are being tested in trial NCT03438396?
The interventions under investigation include: tisotumab vedotin (DRUG).
Who is sponsoring clinical trial NCT03438396?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.